Comorbidity alters the genetic relationship between anxiety disorders and major depression

Authors

Markos Tesfaye M.D., Ph.D.[1,2 *], Alexey Shadrin Ph.D.[1,3], Nadine Parker Ph.D.[1], Piotr Jaholkowski M.D., Ph.D.[1], Pravesh Parekh Ph.D.[1], Gleda Kutrolli Ph.D.[1], Viktoria Birkenæs M.Sc.[1], Nora R. Bakken[1], Helga Ask Ph.D.[4,5], Guy Hindley, M.D. Ph.D[1], Oleksandr Frei Ph.D.[1,6], Srdjan Djurovic Ph.D.[1,7], Anders M. Dale Ph.D.[8,9,10,11], Olav B. Smeland M.D., Ph.D.[1], Kevin S. O'Connell Ph.D.[1], Ole A. Andreassen M.D., Ph.D.[1,3 *]

Affiliations

[1]Centre for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

[2]Department of Psychiatry and Behavioral Sciences, Institute for Genomics in Health, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA.

[3]KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo and Oslo University Hospital, Oslo, Norway

[4]PsychGen Center for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo, Norway

[5]PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway

[6]Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway

[7]Department of Medical Genetics, Oslo University Hospital, Oslo, Norway

[8]Department of Radiology, University of California, San Diego, La Jolla, CA, USA

[9]Multimodal Imaging Laboratory, University of California San Diego, La Jolla, CA, USA

[10]Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA

[11]Department of Neurosciences, University of California San Diego, La Jolla, CA, USA

* Corresponding authors

Markos Tesfaye, M.D., Ph.D. (m.t.woldeyohannes@medisin.uio.no) and
Ole Andreassen, M.D., Ph.D. (o.a.andreassen@medisin.uio.no)
Division of Mental Health and Addiction, Oslo University Hospital &
Institute of Clinical Medicine, University of Oslo
Building 49, Oslo University Hospital, Ullevål,
Kirkeveien 166, PO Box 4956 Nydalen, 0424 Oslo, Norway

Abstract

Background

Comorbid anxiety disorders (ANX) and major depression (MD) have worse clinical outcomes than either disorder alone. Analysis of genomic data based on comorbidity status may reveal more precise biological pathways and causal relationships with potential clinical implications. We investigated the genetic relationship between ANX and MD with and without mutual comorbidity.

Methods

We leveraged data from UK Biobank to perform disorder-specific genome-wide association studies (GWAS) of ANX-only (n=189,422) and MD-only (n=194,339) and generate polygenic risk scores (PRS). The Norwegian Mother, Father, and Child Cohort (MoBa, n = 130,992) served to test the associations of PRS with diagnoses. MD and ANX GWAS, including comorbidities (MD-comorbid and ANX-comorbid), were used for comparison. Genetic correlations were compared by comorbidity status, and Mendelian randomization was employed to assess causal relationships.

Results

The MD-only PRS showed a stronger association with MD-only compared to ANX-only cases (Z=3.74; $P_{adjusted}$=0.002); however, MD-comorbid PRS did not show a significant difference (Z=2.71; $P_{adjusted}$=0.08). The genetic correlation between ANX-only and MD-only was 0.53, lower than between ANX-comorbid and MD-comorbid (0.90). ANX-only showed a causal relationship with MD-only ($P_{adjusted}$=0.015), but not *vice versa*, and contrasted the bidirectional causal relationship ($P_{adjusted}$=2.9e-12, and $P_{adjusted}$=9.3e-06) when comorbidity was included. Gene sets of MD-comorbid, ANX-comorbid, and MD-only, but not of ANX-only, were enriched for immune regulation pathways such as interleukin production.

Conclusions

ANX and MD show more distinct genetics when comorbid cases are excluded, and ANX may be causal for MD. Disorder-specific genetic studies help uncover more relevant biological mechanisms and guide tailored clinical interventions.

Introduction

Anxiety disorders (ANX) and major depression (MD) are the most prevalent psychiatric conditions, making a substantial contribution to poor health and disability globally (1). Both ANX and MD are more prevalent among women (1-3). Comorbidity between the two disorders occurs in over half of all cases (2, 3), and is associated with greater morbidity, worse treatment response, and higher suicide risk (4-6). Overlapping symptomatology, causal relationships, and shared environmental risk factors (7-9) as well as shared genetic risk and neurobiology, may explain the high comorbidity (10, 11).

Both ANX and MD exhibit moderate heritability (12, 13), and consistently show high genetic correlations (10, 14). However, the high comorbidity makes these genetic associations difficult to interpret. The large genome-wide association studies (GWAS) for ANX do not exclude cases of MD, and *vice versa* (14, 15). Polygenic risk scores (PRS) derived from these GWASs exhibit strong associations with comorbid ANX and MD cases (16). We previously reported that the PRS of MD was a stronger predictor of ANX than the PRS of ANX (10). While including individuals with comorbidity may improve the power of GWAS to identify genetic loci (17), such approaches fail to distinguish genes specific to ANX from those specific to MD. Consequently, identifying distinct, disorder-specific, biological mechanisms may be hampered (18). Sub-grouping of ANX and MD by comorbidity status may provide insight into their unique and shared biological mechanisms facilitating the development of tailored treatment strategies. An important approach towards understanding these biological mechanisms is obtaining GWAS of ANX and MD that are sub-grouped by comorbidity status (16, 17).

Here, we investigated the genetic relationship between ANX and MD using two large population-based genotyped samples with clinical psychiatric diagnoses. We removed comorbid ANX-MD cases, conducted ANX-only and MD-only GWAS of the UK Biobank sample, and compared them with GWAS of ANX and MD that included comorbid cases (ANX-comorbid and MD-comorbid). We investigated the genetic relationship between ANX-only and MD-only compared to ANX-comorbid and MD-comorbid, and how the respective PRS associated with ANX and MD diagnoses and symptoms in an independent sample (Norwegian Mother, Father and Child Study, MoBa). We also explored differences in biological pathways and how

comorbidity affected causal relationships between ANX and MD using Mendelian Randomization (MR) (19, 20).

Methods and Materials

We used two large genotyped cohorts with data on relevant psychiatric phenotypes among Europeans for training and testing: the UK Biobank (UKB; Project No. 27412) for GWAS (Training; Supplement 1), and the Norwegian Mother, Father, and Child Cohort (MoBa) for independent testing (Testing; Supplement 1). These cohorts are linked to hospital diagnoses using ICD codes.

Training dataset

We used UKB data to perform GWAS for anxiety disorders (ANX) without comorbid major depression (MD) (ANX-only; cases = 9,980 vs. controls = 179,442) and MD without comorbid ANX (MD-only; cases = 15,301 vs. controls = 179,038).

Diagnoses

The diagnoses are based on hospital records from specialist healthcare services in the UK. Individuals with a history of diagnoses of organic mental disorders (F00 – F09), psychotic disorders (F20 – F29), bipolar disorders (F30.0 – F30.9 and F31.0 – F31.9), or mixed anxiety and depressive disorder (F41.2) were excluded from all analyses. The ANX-only cases were diagnosed with agoraphobia (F40.0), social phobia (F40.1), panic disorder (F41.0), generalized anxiety disorder (F41.1), or other anxiety disorders (F41.3 - F41.9), excluding individuals with 'MD-only' diagnoses (see below). The MD-only cases had a diagnosis of any depressive episode (F32.0 - F32.9), or recurrent depressive disorder (F33.0 - F33.9), excluding individuals with 'ANX-only' diagnoses (see above). Controls for ANX-only (n=179,442) and MD-only (n=179,038) were randomly selected and did not overlap. Individuals with MD were excluded from the ANX-only GWAS control group, and individuals with ANX were excluded from the MD-only GWAS control group.

Comparison GWAS data (inclusive of comorbid cases)

We used publicly available GWAS data without the testing sample (MoBa) of ANX without removing comorbid MD (ANX-comorbid; cases=31,977, controls=82,114) (14), and MD

without removing comorbid ANX (MD-comorbid (cases=170,756, controls=329,443) (15) The MD-comorbid GWAS excluded samples from the UKB and MoBa (Supplement 1). These comorbidity-inclusive GWAS datasets were compared with the training GWAS datasets, which excluded comorbid cases of ANX and MD.

Testing dataset

We obtained genotype and phenotype data on mothers and fathers (n = 130,992) who participated in MoBa (21, 22). All study participants provided written informed consent upon recruitment, and individuals who withdrew during follow-up were excluded from our analyses. The Regional Committee for Medical and Health Research Ethics approved the present study (2016/1226/REK sør-øst C).

Diagnoses

Data on diagnoses of mental disorders were obtained from the Norwegian Patient Registry (2008 - 2022), which comprises specialist psychiatric healthcare diagnoses. We excluded individuals who withdrew their consent (n=484), with missing covariates (n=1,590), were related or had a diagnosis of organic mental disorders (F00 – F09), psychotic disorders (F20 – F29), or bipolar disorders (F30.0 – F30.9 and F31.0 – F31.9) (Supplement 1).

We grouped the cases within the MoBa sample into three disorder-specific subgroups: 1. ANX-only cases (n=1,992) with the same criteria as in the UKB (excluding individuals with MD). 2. MD-only cases (n=7,486) using the same criteria as in the UKB (excluding individuals with ANX). 3. ANX-MD cases (n=3,468) comprising individuals with both MD and ANX or mixed anxiety and depressive disorder (F41.2). The number of individuals with the diagnostic category and controls, as well as reasons for exclusion, are provided in the supplement (Figure S1 in Supplement 1).

Depression and anxiety symptoms

Symptoms of anxiety and depression were assessed using the validated 8-item Hopkins Symptom Checklist (SCL-8), which correlates highly with the original 25-item HSCL (23). Responses were rated on a Likert scale from 1 to 4 reflecting how much respondents were bothered by specific symptoms in the preceding two weeks. Pregnant women participating in

MoBa (n = 67,219) completed the SCL-8 during the 30th week of gestation. After excluding individuals with missing covariates (n=787) and related individuals (n=11,570), the analysis included 54,862 mothers (Figure S2 in Supplement 1).

Genetic analysis

Genotype data.

UKB: DNA was extracted from blood samples and genome-wide genotyping was performed using the UK BiLEVE and UK Biobank Axiom arrays. Genotype imputation and centralized quality control procedures for the UKB genotypes are described in detail elsewhere (24).

MoBa: The Norwegian Institute of Public Health oversaw the blood sample storage and DNA extraction (https://www.fhi.no/en/publ/2012/protocols-for-moba/). Genotyping was performed using genome-wide arrays, and the genetic data were imputed and processed for quality control using a family-based pipeline (https://github.com/psychgen/MoBaPsychGen-QC-pipeline) (25). We limited our analyses to data from individuals of European ancestry.

Genome-wide association studies (GWAS)

We performed ANX-only and MD-only GWAS using version 3 of the UKB genetic data among individuals of "white British" ancestry classified according to self-declared ethnicity and genetic principal component (PC) analysis (as defined by UKB data field 22006). We conducted the analyses using REGENIE v3.4.1, applying an approximate Firth logistic regression (26). This approach allows the inclusion of related individuals in the analysis and efficiently handles samples with unbalanced case-control ratios. Age, sex, and the first 20 genotype PCs were included as covariates. Variants with an imputation INFO score < 0.8, minor allele count < 20, and non-autosomal variants were excluded from the association testing, resulting in 19,201,831 variants tested in ANX-only and 19,238,272 variants tested in MD-only GWAS.

Polygenic risk score (PRS)

PRSs were derived from GWAS of ANX-only and MD-only GWAS. In addition, PRSs were derived from GWAS of ANX and MD inclusive of comorbid cases, i.e., ANX-comorbid (14) and MD-comorbid (15). All PRSs were computed using the PRS-PCA approach, extracting PCs

PRSs generated by PRSice (2.3.3) for a set of *p*-value cut-offs (1.0e-06, 1.0e-05, 1.0e-04, 1.0e-03, 1.0e-02, 5.0e-02, 1.0e-01, 5.0e-01, 1.0) (27). The PRSs were used to predict phenotypes (diagnoses, symptoms) in the MoBa sample, applying the first PC in logistic regression models.

Statistical analysis

PRS associations

Logistic regression analyses were performed to test the association between each PRS (i.e., ANX-only, MD-only, MD-comorbid, and ANX-comorbid) in the training sample, and each diagnostic category in the test (MoBa) sample (i.e., ANX-only, MD-only, and ANX-MD) case-control comparisons. Additionally, logistic regression was used to assess whether each PRS is differentially associated with one diagnostic category over another in case-case comparisons.

For depression and anxiety symptoms, responses were dichotomized into '1' for '3- Quite bothered' or '4- Very bothered', and '0' for '1- Not bothered' or '2- A little bothered'. Logistic regressions were used to analyze the association between each PRS and the symptoms. All regression models were adjusted for age, sex, and the first 10 genotype PCs. Only one of the related individuals with a kinship coefficient greater than 0.05 was kept, prioritizing cases. Effect sizes were represented as standardized β values with 95% confidence intervals. Bonferroni correction was applied to *p*-values to account for multiple comparisons. The strength of associations (regression coefficients) of the different PRS with a specific phenotype was compared using independent Z-test.

Genetic Correlations

Linkage disequilibrium score regression (28) was applied to the GWAS summary data to estimate genetic correlations between ANX and MD with or without comorbid cases. The single nucleotide polymorphism (SNP) heritability for each phenotype was also computed.

Mendelian Randomization (MR)

We applied MR analyses using the R package TwoSampleMR (29) to examine causal associations between ANX and MD. These analyses were performed following the STROBE-MR guidelines (30). We applied inverse variance weighted (IVW) to highlight causal associations between ANX and MD (19). Additionally, sensitivity analyses including weighted

median (31), and MR Egger (32) methods were applied as sensitivity analyses, and to rule out confounding arising from horizontal pleiotropy (20). Instruments were selected at a *p*-value threshold of 1e-05 to account for the low power of the ANX-only and MD-only GWASs (33), following previous studies' application of a more relaxed p-value threshold for low-power GWASs (34, 35). These analyses were performed using TwoSampleMR (version 0.5.8), and MRPRESSO (version 1.0). The resulting p-values were corrected for multiple testing using the Benjamini-Hochberg method.

Functional Enrichment of Genes

To identify and compare the biological mechanisms of ANX and MD, we employed GSA-MiXeR, which can provide more specific genes and pathways relevant to a given phenotype. GSA-MiXeR estimates gene-level heritability for individual genes from the respective GWAS summary statistics. Fold enrichment for each gene can then be computed by calculating the ratio of the gene-level heritability estimated by the full model and the gene-level heritability estimated using a simplified baseline model, which assumes that genetic effects are evenly spread across the genome (36). Enrichment of genes and pathways with Akaike Information Criterion (AIC) value greater than zero was considered reliable. We compared the enriched genes for ANX-only and MD-only as well as ANX-comorbid and MD-comorbid based on AIC and fold enrichment values.

Results

Sample characteristics

UKB data: ANX-only case-control sample consisted of 189,422 (54.0 % females) with a mean age(SD) of 56.8 (8.0) years. MD-only case-control sample comprised 194,339 participants (54.1 % females) with a mean age (SD) of 56.7 (8.0) years. *MoBa data:* A total of 128,918 individuals (58.9% females) with a mean age (SD) of 49.0 (5.4) years had genetic and diagnostic data. For the prediction of symptoms of anxiety and depression, the sample included 54,862 mothers with a mean age (SD) of 48.1 (5.0) years.

PRS associations with diagnoses in MoBa

To investigate the impact of removing comorbid cases from the GWAS in the training sample (UKB), we compared the associations of PRS from the different GWAS in the test sample (MoBa) (Table 1, Figure 1). The PRS from comorbidity-exclusive MD-only showed stronger associations with MD-only or ANX-MD cases than with ANX-only cases. In contrast, the PRS of MD-comorbid showed stronger associations with ANX-MD cases than both MD-only and ANX-only cases. The PRS of ANX-comorbid was associated with ANX-only and MD-only cases to a similar degree but showed a stronger association with ANX-MD than with MD-only cases. The PRS from ANX-only showed a stronger association with ANX-only cases than MD-only cases, although the difference was not statistically significant (Table 1, Figure 1). This may be a result of the relatively small sample sizes of ANX both in the training and test samples. The patterns of PRS-diagnostic category associations are depicted as differential associations in the case-case comparisons (Figure S3, Supplement 1).

PRS associations with depression and anxiety symptoms

To investigate how comorbidity between ANX and MD affects genetic relationships beyond diagnostic categories, we tested the association of the PRSs with depression and anxiety symptoms measured in MoBa. MD-comorbid PRS was associated with all eight SCL-8 items, consistent with the inclusion of comorbid ANX in the GWAS. ANX-only PRS was significantly associated with all anxiety items but only two depression items (‘feeling blue’ and ‘feeling everything is an effort’). MD-only PRS was associated with all items except one anxiety item (‘suddenly scared for no reason’) (Figure 2, Table S1 in Supplement 2). Overall, all PRS

associations at the symptom level align with the findings on the diagnostic groups level (Figure 1).

Genetic Correlation and Mendelian Randomization (MR)

To further investigate the genetic relationship between ANX and MD, we applied genetic correlation and MR analyses. The genetic correlation between MD-comorbid and ANX-comorbid was higher (0.90; SE = 0.03, p = 5.4e-196) than between MD-only and ANX-only (0.53; SE = 0.11, p = 2.7e-06), illustrating that the comorbidity contributes to the high genetic correlation. SNP heritability was 6.9% for MD-comorbid, 9.5% for ANX-comorbid, 10.5% for MD-only, and 5.4% for ANX-only.

Two MR methods showed evidence of a bidirectional causal relationship between MD-comorbid and ANX-comorbid; however, the potential confounding effect of including comorbid ANX and MD in the GWAS limits the interpretation. Without these comorbidities, ANX-only showed evidence of causal association with MD-only, but not *vice versa* (Table 2).

Enrichment of Genes and Pathways

GSA-MiXeR analyses identified significant fold enrichment for 148 genes in ANX-only (113 unique) and 155 genes in MD-only (114 unique), with 13 genes enriched in both (*ERBB4, ACSL3, TPRG1, MAML3, KCNQ5, INSIG1, KCNB2, FER1L6, B3GLCT, IRX6, TSHZ3, TOX2*, and *FAM110A*). Enriched pathways for ANX-only included: microvesicle, CCR6 chemokine receptor binding, and cardiac muscle myoblast proliferation (Table S2 in Supplement 2). For MD-only, pathways included negative regulation of myoblast proliferation, interleukin 21 production, protein-O-linked fucosylation, and positive regulation of 3-UTR-mediated mRNA stabilization (Table S3 in Supplement 2). More genes showed enrichment in ANX-comorbid (n=190) and MD-comorbid (n=331) (Tables S4 & S5 in Supplement 2), with 48 genes common to both (Figure 3).

Discussion

Here, we dissected the genetic relationship between ANX and MD using samples with and without comorbid cases. The genetic correlation between ANX and MD was significantly reduced after excluding comorbid cases. While the MD-only PRS was better at distinguishing the different phenotypes than the MD-comorbid PRS, both at the diagnostic and symptom levels, a significant association remained with the ANX-MD cases, suggesting residual genetic overlap. The MR results suggest a causal association of ANX with MD. These findings, together with the pattern of diagnosis-specific and shared genes, suggest that MD and ANX may have distinct underlying biological pathways, separate from the shared pathways in the comorbid subgroups.

Our MR results from the non-comorbidity analyses suggest that ANX is causal to MD, and not *vice versa*. This aligns with the results of epidemiological studies (7, 8, 37), which showed that ANX often precedes MD (8, 38, 39). Further, longitudinal clinical findings also support that ANX causes MD but not *vice versa* (7). A large proportion of individuals with MD (46 - 75%) have a history of ANX, which is associated with greater severity, chronicity, and impairment (39-42). Furthermore, the importance of anxiety symptoms in MD has also been highlighted with the anxious distress specifier in DSM-5 (43, 44). Therefore, targeting ANX symptoms in the early phase of MD may improve clinical outcomes. These findings also question the bidirectional causal association observed using the GWAS of MD and ANX with comorbidity.

PRS of MD without comorbidity were differentially associated with non-comorbid MD and ANX diagnoses, while the PRS of MD with comorbidity showed little difference. A similar pattern was observed at the symptom level. This shows that the MD PRS from GWAS excluding comorbid cases may perform better in distinguishing between cases of ANX and MD. A large study using biobank samples recently showed that the PRS of MD with comorbidity had a stronger association with comorbid (ANX-MD) cases than with MD-only cases (16). Furthermore, ANX and MD without comorbidity showed only a moderate genetic correlation (r_g = 0.53), contrasting the high genetic correlation observed for ANX and MD with comorbidity (r_g = 0.90). In support, a recent family-based adoption study from Sweden showed a decrease in the genetic correlation from 0.83 to 0.46 after re-classification of cases into primary ANX or primary MD by applying diagnostic hierarchy (45). Another study showed that fear-based anxiety phenotypes had lower genetic correlation with depression than generalized anxiety phenotype (46).

The range of positive association between symptoms (SCL-8) and the different PRS was consistent with the assertion that self-report symptoms indicate general dysphoria and could be associated with different disorder-specific PRS (47) and with the significant phenotypic correlations across anxiety and depressive symptoms (48). Our findings may have potential clinical applications, e.g., sub-grouping patients with MD for treatment selection or predicting prognosis. Disorder-specific genetic risk may also have implications for predicting treatment outcomes (49, 50).

Our investigation of enriched genes based on heritability revealed that a larger proportion (25%) of genes overlapped between ANX and MD with comorbidity, compared to only 10% observed for ANX and MD without comorbidity. It is important to conduct GWAS on well-defined MD phenotypes to identify MD-specific biological pathways (18). Consistent with this, interleukin-21 production is enriched in our gene sets for MD with and without comorbidity, but not for ANX-only. These findings support the notion that ANX and MD have partially independent genetic underpinnings (16). Distinct from these genetic pathways, we identified 34 enriched genes overlapping between the comorbidity-inclusive MD and ANX groups.

Current efforts to improve genetic discoveries in complex phenotypes emphasize increasing sample sizes (51). Although more inclusive and less stringent case selection can increase the power of GWAS (18), it may also hinder discoveries essential for precision medicine. Notably, it adds to the phenotypic heterogeneity which impedes the discovery of sub-group-specific genetic loci (17). Thus, investigating the genetic relationships between diagnoses with pervasive comorbidity without proper control for comorbid cases in the GWAS may provide misleading results both regarding genetic architecture as well as functional annotations. The inclusion of comorbid cases in GWASs may have inflated the reported genetic overlap and shared loci between ANX and MD (10, 14). Current genome-wide approaches for ANX and MD might overlook some biological pathways related to only one of these disorders. As larger samples become available, GWAS for these sub-groups of patients is a logical next step in the service of advancing equitable precision medicine.

Our findings should be interpreted in the light of some limitations. The cases were defined based on available hospital diagnosis data and may include some undetected comorbid cases. However, this would bias the results towards less differences and reduce the likelihood of type I errors. The

different statistical power across both training and testing samples may affect the results, such as the effect estimates for the association between MD-comorbid PRS and ANX caseness. However, the effect directions were consistent. Since the SNP heritabilities for ANX and MD were comparable to previous reports (14, 15), low power alone is unlikely to explain the diminished genetic correlation (28, 52). Stronger genetic burden among comorbid cases (53) and an overrepresentation of comorbid cases in GWAS samples (15) could also affect statistical power. Additionally, diagnostic hierarchy requires the exclusion of MD before diagnosing ANX but not *vice versa* (44), which may lead to underreporting of ANX among individuals with MD (54). Both the UKB and MoBa data used in these analyses are predominantly white European populations, and of higher educational levels than the general populations, which need consideration in the interpretation of the findings.

In conclusion, the current findings show that genetic liabilities for ANX and MD are more distinct than inferred from GWAS where comorbid cases were included, and provide support for a comorbid group arising from true genetic pleiotropy. The results also implicate more specific underlying biological pathways across the ANX-MD spectrum. The findings also suggest that ANX may have a causal link to MD, providing support for the treatment of ANX symptoms to prevent MD. Together, genetic factors derived from ANX and MD excluding comorbidities may facilitate the development of precision medicine approaches and identification of novel biological mechanisms for tailored interventions.

Conflict of Interest Disclosures

Ole A. Andreassen is a consultant for Cortechs.ai and Precision Health and has received speaker's honoraria from Lundbeck, Janssen, Otsuka, and Sunovion. Srdjan Djurovic has received speaker's honoraria from Lundbeck. Dr. Anders M. Dale is the Founding Director, holds equity in CorTechs Labs, Inc. (DBA Cortechs.ai), and serves on its Board of Directors and the Scientific Advisory Board. He is an unpaid consultant for Oslo University Hospital. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. Dr. Frei is a consultant to Precision Health. The other authors have no conflicts of interest to declare.

Funding/Support

The authors received support support from the Research Council of Norway (324252, 324499, 300309, 273291, 223273, 248778, 273446, 326813, 334920, 271555/F21, 324620), NordForsk (grant 156298), the European Economic Area and Norway Grants (EEA-RO-NO-2018-0535, EEA-RO-NO-2018-0573), the South-East Norway Regional Health Authority (2022-087 and 2022-073), The University of Oslo, KG Jebsen Stiftelsen (SKGJ-MED-021), the European Union's Horizon 2020 research and innovation program (847776, 964874), and Marie Skłodowska-Curie grant (801133), and the US National Institutes of Health (R01MH123724-01, R01MH124839-02, U24DA041123, R01AG076838, U24DA055330, and OT2 HL161847). This work was supported by the National Institutes of Health grants R01MH125938 (MT). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies and the National Institutes of Health. The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (grant 229624). The Norwegian Centre for Mental Disorders Research (NORMENT) provided genotype data, funded by the Research Council of Norway (grant 223273), South East Norway Health Authorities, and Stiftelsen Kristian Gerhard Jebsen. The Center for Diabetes Research, the University of Bergen, provided genotype data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and theWestern Norway Health Authorities.

Additional Contributions: We are grateful to all individuals who participated in the Norwegian MoBa study. We thank the Norwegian Institute of Public Health for generating high-quality genomic data. We also thank the research participants and employees of the Psychiatric Genomic Consortium (Anxiety Disorders, and Major Depressive Disorder Working Groups), the UK Biobank, and iPSYCH.

Additional Information: This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no). This research has been conducted using the UK Biobank Resource under Application Number 27412.

References

1. Collaborators GBDMD (2022): Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry*. 9:137-150.
2. Penninx BW, Pine DS, Holmes EA, Reif A (2021): Anxiety disorders. *Lancet*. 397:914-927.
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003): The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA*. 289:3095-3105.
4. Ter Meulen WG, Draisma S, van Hemert AM, Schoevers RA, Kupka RW, Beekman ATF, Penninx B (2021): Depressive and anxiety disorders in concert-A synthesis of findings on comorbidity in the NESDA study. *J Affect Disord*. 284:85-97.
5. Zhou Y, Cao Z, Yang M, Xi X, Guo Y, Fang M, et al. (2017): Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder. *Sci Rep*. 7:40511.
6. Kalin NH (2020): The Critical Relationship Between Anxiety and Depression. *Am J Psychiatry*. 177:365-367.
7. Mathew AR, Pettit JW, Lewinsohn PM, Seeley JR, Roberts RE (2011): Co-morbidity between major depressive disorder and anxiety disorders: shared etiology or direct causation? *Psychol Med*. 41:2023-2034.
8. Wittchen HU, Kessler RC, Pfister H, Lieb M (2000): Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. *Acta Psychiatr Scand Suppl*.14-23.
9. Thorp JG, Campos AI, Grotzinger AD, Gerring ZF, An J, Ong JS, et al. (2021): Symptom-level modelling unravels the shared genetic architecture of anxiety and depression. *Nat Hum Behav*. 5:1432-1442.
10. Tesfaye M, Jaholkowski P, Shadrin AA, van der Meer D, Hindley GFL, Holen B, et al. (2024): Identification of novel genomic loci for anxiety symptoms and extensive genetic overlap with psychiatric disorders. *Psychiatry Clin Neurosci*. 78:783-791.
11. Hettema JM (2008): What is the genetic relationship between anxiety and depression? *Am J Med Genet C Semin Med Genet*. 148C:140-146.
12. Shimada-Sugimoto M, Otowa T, Hettema JM (2015): Genetics of anxiety disorders: Genetic epidemiological and molecular studies in humans. *Psychiatry Clin Neurosci*. 69:388-401.
13. Sullivan PF, Neale MC, Kendler KS (2000): Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry*. 157:1552-1562.
14. Purves KL, Coleman JRI, Meier SM, Rayner C, Davis KAS, Cheesman R, et al. (2020): A major role for common genetic variation in anxiety disorders. *Mol Psychiatry*. 25:3292-3303.
15. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. (2019): Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci*. 22:343-352.
16. Coombes BJ, Landi I, Choi KW, Singh K, Fennessy B, Jenkins GD, et al. (2023): The genetic contribution to the comorbidity of depression and anxiety: a multi-site electronic health records study of almost 178 000 people. *Psychol Med*. 53:7368-7374.
17. Crouch DJM, Bodmer WF (2020): Polygenic inheritance, GWAS, polygenic risk scores, and the search for functional variants. *Proc Natl Acad Sci U S A*. 117:18924-18933.
18. Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM, et al. (2020): Minimal phenotyping yields genome-wide association signals of low specificity for major depression. *Nat Genet*. 52:437-447.
19. Burgess S, Butterworth A, Thompson SG (2013): Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. 37:658-665.

20. Morrison J, Knoblauch N, Marcus JH, Stephens M, He X (2020): Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. *Nat Genet*. 52:740-747.
21. Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, et al. (2016): Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol*. 45:382-388.
22. Paltiel L, Haugen A, Skjerden T, Harbak K, Bækken S, Strensrud NK, et al. (2014): The biobank of the Norwegian Mother and Child Cohort Study – present status. *Nor J Epidemiol*. 24:29-35.
23. Tamb K, Røysamb E (2014): Selection of questions to short-form versions of original psychometric instruments in MoBa. *Norsk Epidemiologi*. 24:195 - 201.
24. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. (2018): The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 562:203-209.
25. Corfield EC, Frei O, Shadrin AA, Rahman Z, Lin A, Athanasiu L, et al. (2022): The Norwegian Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen pipeline v.1. *bioRxiv*.2022.2006.2023.496289.
26. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. (2021): Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet*. 53:1097-1103.
27. Coombes BJ, Ploner A, Bergen SE, Biernacka JM (2020): A principal component approach to improve association testing with polygenic risk scores. *Genet Epidemiol*. 44:676-686.
28. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics C, et al. (2015): LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 47:291-295.
29. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. (2018): The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. 7.
30. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. (2021): Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA*. 326:1614-1621.
31. Bowden J, Davey Smith G, Haycock PC, Burgess S (2016): Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*. 40:304-314.
32. Bowden J, Davey Smith G, Burgess S (2015): Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 44:512-525.
33. Cheng W, Parker N, Karadag N, Koch E, Hindley G, Icick R, et al. (2023): The relationship between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study. *Lancet Psychiatry*. 10:441-451.
34. Li F, Tang M, Hao C, Yang M, Pan Y, Lei P (2024): Brain imaging traits and epilepsy: Unraveling causal links via mendelian randomization. *Brain Behav*. 14:e70051.
35. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Vosa U, et al. (2019): Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *Nat Genet*. 51:600-605.
36. Frei O, Hindley G, Shadrin AA, van der Meer D, Akdeniz BC, Hagen E, et al. (2024): Improved functional mapping of complex trait heritability with GSA-MiXeR implicates biologically specific gene sets. *Nat Genet*. 56:1310-1318.
37. Wittchen HU, Beesdo K, Bittner A, Goodwin RD (2003): Depressive episodes--evidence for a causal role of primary anxiety disorders? *Eur Psychiatry*. 18:384-393.
38. Ohayon MM, Schatzberg AF (2010): Social phobia and depression: prevalence and comorbidity. *J Psychosom Res*. 68:235-243.

39. Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al. (2015): Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. *Epidemiol Psychiatr Sci*. 24:210-226.
40. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. (2008): Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. *Am J Psychiatry*. 165:342-351.
41. Wiethoff K, Bauer M, Baghai TC, Moller HJ, Fisher R, Hollinde D, et al. (2010): Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. *J Clin Psychiatry*. 71:1047-1054.
42. Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJ, et al. (2011): Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). *J Clin Psychiatry*. 72:341-348.
43. Gaspersz R, Lamers F, Kent JM, Beekman AT, Smit JH, van Hemert AM, et al. (2017): Longitudinal Predictive Validity of the DSM-5 Anxious Distress Specifier for Clinical Outcomes in a Large Cohort of Patients With Major Depressive Disorder. *J Clin Psychiatry*. 78:207-213.
44. APA (2013): *American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders*. Fifth ed. Arlington, VA: American Psychiatric Association.
45. Kendler KS, Abrahamsson L, Ohlsson H, Sundquist J, Sundquist K (2022): An Extended Swedish Adoption Study of Anxiety Disorder and Its Cross-Generational Familial Relationship With Major Depression. *Am J Psychiatry*. 179:640-649.
46. Morneau-Vaillancourt G, Coleman JRI, Purves KL, Cheesman R, Rayner C, Breen G, Eley TC (2020): The genetic and environmental hierarchical structure of anxiety and depression in the UK Biobank. *Depress Anxiety*. 37:512-520.
47. Huang L, Tang S, Rietkerk J, Appadurai V, Krebs MD, Schork AJ, et al. (2024): Polygenic Analyses Show Important Differences Between Major Depressive Disorder Symptoms Measured Using Various Instruments. *Biol Psychiatry*. 95:1110-1121.
48. Vaccarino AL, Evans KR, Sills TL, Kalali AH (2008): Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression. *Depress Anxiety*. 25:1006-1013.
49. Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, et al. (2017): Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. *J Psychiatr Res*. 91:1-13.
50. Hicks PB, Sevilimedu V, Johnson GR, Tal IR, Chen P, Davis LL, et al. (2023): Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report. *Psychiatr Res Clin Pract*. 5:131-143.
51. Abdellaoui A, Yengo L, Verweij KJH, Visscher PM (2023): 15 years of GWAS discovery: Realizing the promise. *Am J Hum Genet*. 110:179-194.
52. van Rheenen W, Peyrot WJ, Schork AJ, Lee SH, Wray NR (2019): Genetic correlations of polygenic disease traits: from theory to practice. *Nat Rev Genet*. 20:567-581.
53. Tabrizi F, Rosen J, Gronvall H, William-Olsson VR, Arner E, Magnusson PK, et al. (2025): Heritability and polygenic load for comorbid anxiety and depression. *Transl Psychiatry*. 15:98.
54. Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB (2001): Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. *J Abnorm Psychol*. 110:585-599.

Figure Legends:

Figure 1. The association of PRS of differently defined anxiety and depressive disorders with anxiety disorder only (ANX-only cases), major depression only (MD-only cases), or comorbid anxiety and depression (ANX-MD cases) compared to controls (CTRL). PRS: polygenic risk score; CI: confidence interval, ANX-comorbid: anxiety disorder including comorbid depression, MD-comorbid: major depression including comorbid anxiety. Phenotypes are displayed on the x-axis and PRS on the y-axis.

Figure 2. The association of polygenic scores (PRS) of differently defined anxiety and depressive disorders with symptoms of depression (Blue, Effort, Hopeless, Worry) and symptoms of anxiety (Nervous, Fearful, Scared, Tension) reported by mothers from MoBa. ANX-comorbid: anxiety disorder including comorbid depression, MD-comorbid: major depression including comorbid anxiety, ANX-only: anxiety disorder only, and MD-only: major depression only.

Figure 3. Venn diagram – The numbers of genes that showed enrichment in GSA-MiXeR analyses using GWAS data for different diagnoses. ANX-comorbid: anxiety disorder including comorbid depression, MD-comorbid: major depression including comorbid anxiety, ANX-only: anxiety disorder only, MD-only: major depression only.

Table 1: Comparison of the strength of associations of polygenic scores with phenotypes by comorbidity status in the MoBa cohort.

Polygenic scores	**Effect estimates on outcome phenotypes**				**Effect differences**		
	MD-only (Cs: 7,486; Cn: 83,146)		ANX-only (Cs: 1,992; Cn: 85,851)				
	β coefficient	SE	β coefficient	SE	Z-score	P-value	Adjusted P
MD-only	**0.128**	**0.013**	**0.048**	**0.017**	**3.738**	**1.9e-04**	**2.2e-03**
ANX-only	0.059	0.013	0.089	0.017	-1.402	1.6e-01	1.00
ANX-comorbid	0.157	0.013	0.184	0.017	-1.262	2.1e-01	1.00
MD-comorbid	0.257	0.013	0.199	0.017	2.710	6.7e-03	8.0e-02
	MD-only		ANX-MD (Cs: 3,468; Cn: 85,107)				
MD-only	0.128	0.013	0.148	0.016	-0.970	3.3e-01	1.00
ANX-only	0.059	0.013	0.085	0.016	-1.261	2.1e-01	1.00
ANX-comorbid	**0.157**	**0.013**	**0.237**	**0.016**	**-3.881**	**1.0e-04**	**1.2e-03**
MD-comorbid	**0.257**	**0.013**	**0.325**	**0.017**	**-3.178**	**1.5e-03**	**1.8e-02**
	ANX-only		ANX-MD				
MD-only	**0.048**	**0.017**	**0.148**	**0.016**	**-4.284**	**1.8e-05**	**2.2e-04**
ANX-only	0.089	0.017	0.085	0.016	0.171	8.6e-01	1.00
ANX-comorbid	0.184	0.017	0.237	0.016	-2.270	2.3e-02	2.8e-01
MD-comorbid	**0.199**	**0.017**	**0.325**	**0.017**	**-5.241**	**1.6e-07**	**1.9e-06**

ANX-comorbid: anxiety disorder including comorbid depression, MD-comorbid: major depression including comorbid anxiety, ANX-MD: comorbid anxiety and depression, ANX-only: anxiety disorder only, MD-only: major depression only, SE – standard error, Cs – number of cases, Cn – number of controls.

Table 2. Bidirectional Mendelian Randomization Analyses of Anxiety Disorders and Major Depression

Exposure	Outcome	Method	SNPs	Beta	SE	P-value	Adjusted P
MD-comorbid[1]	ANX-comorbid	**IVW**	**47**	**0.48**	**0.06**	**2.17e-14**	**1.73e-13**
		MR Egger	47	0.03	0.20	0.88	0.93
		Weighted Median	**47**	**0.37**	**0.08**	**2.33e-06**	**9.31e-06**
ANX-comorbid[1]	MD-comorbid	**IVW**	**39**	**0.26**	**0.03**	**2.17e-24**	**3.47e-23**
		MR Egger	39	-0.19	0.25	0.46	0.73
		Weighted Median	**39**	**0.11**	**0.02**	**5.40e-13**	**2.88e-12**
MD-only[1]	ANX-only	IVW	25	0.01	0.05	0.78	0.89
		MR Egger	25	0.01	0.13	0.93	0.93
		Weighted Median	25	0.02	0.07	0.78	0.89
ANX-only[1]	MD-only	**IVW**	**23**	**0.10**	**0.04**	**1.43e-02**	**3.81e-02**
		MR Egger	23	-0.13	0.10	0.18	0.36
		Weighted Median	**23**	**0.15**	**0.05**	**4.79e-03**	**1.53e-02**

[1] Instruments were selected at a *p*-value threshold of 1e-05; *p*-values < 0.05 after correction are in bold.
ANX-comorbid: anxiety disorder including comorbid depression, MD-comorbid: major depression including comorbid anxiety, ANX-only: anxiety disorder only, MD-only: major depression only, SE – standard error, IVW – inverse variance weighted, MR – Mendelian randomization


PRS
Estimate (95% CI)
CTRL
ANX-only
MD-only
ANX-MD
MD-only
0.05 (0.01, 0.08)
0.13 (0.10, 0.15)
0.15 (0.12, 0.18)
ANX-only
0.09 (0.05, 0.12)
0.06 (0.03, 0.08)
0.09 (0.05, 0.12)
ANX-comorbid
0.18 (0.15, 0.22)
0.16 (0.13, 0.18)
0.24 (0.20, 0.27)
MD-comorbid
0.20 (0.17, 0.23)
0.26 (0.23, 0.28)
0.32 (0.29, 0.36)
-0.2
0.0
0.2
0.4
Estimate (95% CI)
p-value
(Bonferroni-adjusted)
Significant
Not Significant


PRS
Blue
Effort
Hopeless
Worry
Scared
Tension
Nervous
Fearful
MD-only
ANX-only
ANX-comorbid
MD-comorbid
-0.1 0 0.1 0.3
Estimate (95% Confidence Interval)
p-value
(Bonferroni-adjusted)
Not Significant
Significant


ANX-only
MD-only
MD-comorbid
ANX-comorbid
113
114
13
8
4
253
1
2
131
2
16
5
8
4
34